09 Aug 2013
Results of a phase 2 trial of teplizumab, a CD3-targetted antibody designed to arrest T cell-mediated autoimmune response against pancreatic beta cells, are published in Diabetes.
ITN type 1 diabetes study identifies subset of patients with strong response to therapy (EurekAlert, 15 August 2013)
A further study of teplizumab, also in Diabetes, assesses C-peptide responses to teplizumab among 77 new-onset patients aged 8 to 30 years old.
Call for nominations for Awards Committee Chair
30 Oct 2024
James M Tanner Award - 2025 nominations open
30 Oct 2024
Would you like to host the BSPED annual meeting?
21 Oct 2024